Recursion (RXRX) Stock Surges on AI-Driven Breakthroughs and Big-Pharma Deals
Recursion Pharmaceuticals (NASDAQ: RXRX) is a Salt Lake City–based clinical-stage “TechBio” biotech that uses AI, automation and massive biological datasets to speed drug discovery ts2.tech. In early October 2025 the stock showed wild swings: it plunged to the mid-$5s then rebounded ~16% on Oct 8 after an AI-focused tech conference and pipeline news ts2.tech ts2.tech. As of mid-day Oct 16, RXRX trades around $6.5, having closed at ~$6.79 on Oct 16 insidermonkey.com. This volatility reflects renewed investor interest in Recursion’s AI platform and upcoming trial readouts. Key Facts Recent Stock Performance Recursion’s share price has been unusually volatile in October